{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Mexico Drug Manufacturers - Specialty & Generic news", "home_page_url": "https://sharemaestro.com/newsreel/mx/healthcare/drug-manufacturers-specialty-generic/", "feed_url": "https://sharemaestro.com/newsreel/mx/healthcare/drug-manufacturers-specialty-generic/feed.json", "description": "Latest Drug Manufacturers - Specialty & Generic company headlines from Mexico, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:75945c1d5efeb098163b135d5abb4ce99219477d7736af6fc2e6f09753d896bb", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-receives-emergency-authorization-simparica-195100958.html", "title": "Zoetis Receives Emergency Use Authorization for Simparica Trio\u00ae (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies", "content_text": "Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and livestock PARSIPPANY, N.J., August 13, 2026--(BUSINESS WIRE)--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia", "date_published": "2026-08-13T19:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}, {"id": "source:356b9804c9a950cf8dc50d3ef8ffae3b5a2bb261fcdebe7b7d66a4ec0cf11c6d", "url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/zoetis-zts-q2-2026-earnings-call-transcript", "title": "Zoetis (ZTS) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on a reported basis and a 1% decline on an organic operational basis driven by a 1% decrease in volume.Adjusted Net Income -- $781 million, declining 2% on an organic operational basis.Adjusted Diluted EPS -- $1.87, representing 4% growth year over year and benefiting from a lower share count.U.S. Segment Revenue ", "date_published": "2026-08-13T12:01:05+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}, {"id": "source:3f71d45c0573f69153a6e39a25e9d4f128836f975024337ca79b990cc88aab05", "url": "https://finance.yahoo.com/m/a1d3cbfb-8db8-3ad0-a49f-21941c47a99c/is-hims-the-next-big-name-in.html", "external_url": "https://finance.yahoo.com/m/a1d3cbfb-8db8-3ad0-a49f-21941c47a99c/is-hims-the-next-big-name-in.html", "title": "Is Hims The Next Big Name In Peptides? Shares Topple Despite Sales Beat.", "content_text": "Hims stock toppled Tuesday. Analysts are watching the telehealth giant's move closer to the peptide segment. Continue Reading", "date_published": "2026-08-11T20:03:18+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:1166527e9b60404a5f04115bd78d896eee5f6d77aab3b476233fe8eecc57122d", "url": "https://finance.yahoo.com/markets/stocks/articles/hims-hers-stock-plunges-post-171900613.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/hims-hers-stock-plunges-post-171900613.html", "title": "Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down", "content_text": "Hims & Hers Health, Inc. HIMS reported quarterly adjusted loss per share of 10 cents in second-quarter 2026, against the year-ago period's adjusted earnings per share (EPS) of 17 cents. The metric was wider than the Zacks Consensus Estimate of loss per share of 7 cents. GAAP loss per share for the quarter was 37 cents against the year-ago period's EPS of 17 cents. HIMS' Revenues in Detail Hims & Hers registered revenues of $753.2 million in the second quarter, up 38.2% year over year. The figure surpassed the Zacks Consensus Estimate by 9.1%. Solid revenues from both geographic segments drove ", "date_published": "2026-08-11T17:19:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:79c844264423e272aa2867670c91c454e26008f565aaa5d0cc3a9728868259f8", "url": "https://finance.yahoo.com/markets/stocks/articles/hims-hers-higher-2026-revenue-161514631.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/hims-hers-higher-2026-revenue-161514631.html", "title": "Will Hims & Hers\u2019 Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS\u2019s Investment Narrative?", "content_text": "Hims & Hers Health, Inc. reported second-quarter 2026 sales of US$753.21 million, up from US$544.83 million a year earlier, but moved from net income of US$42.51 million to a net loss of US$86.29 million, while also raising full-year 2026 revenue guidance to between US$3.10 billion and US$3.30 billion and issuing higher third-quarter revenue expectations. Alongside this growth outlook, the company is rolling out an AI-powered, personalized weight loss experience on the Hers app, supported by a connected smart scale, and is investing in international expansion, even as margin pressures, an FTC ", "date_published": "2026-08-11T16:15:14+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:2db1209baecde392f18de882446c7f3d6f34e613049d4c244f65e2576fac3d3e", "url": "https://finance.yahoo.com/markets/stocks/article/hims--hers-stock-trims-losses-following-quarterly-results-155021166.html", "external_url": "https://finance.yahoo.com/markets/stocks/article/hims--hers-stock-trims-losses-following-quarterly-results-155021166.html", "title": "Hims & Hers stock trims losses following quarterly results", "content_text": "What happened: Hims & Hers Health (HIMS) stock declined 3% before trimming losses on Tuesday. What's behind the move: Shares were volatile after the telehealth company swung to a loss of $0.37 per share in the second quarter from a profit of $0.17 a share in the year-earlier period. Gross margins in the second quarter were 64%, down from 76% in the year-earlier period. The results were impacted by a one-time cost of $81 million during the quarter, including expenses related to the acquisition of the Australian-based digital health company Eucalyptus. The expenses were also related to restructu", "date_published": "2026-08-11T15:50:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:d7a3f4942ee1362802f00abd1085db3bc118b15946f8d0711b9a97ffa80008e7", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-q2-revenue-beat-153500258.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-q2-revenue-beat-153500258.html", "title": "Hims & Hers Q2 revenue beat offset by wider-than-expected loss", "content_text": "Hims & Hers Q2 revenue beat offset by wider-than-expected loss Proactive uses images sourced from Shutterstock Hims & Hers Health (NYSE:HIMS) delivered mixed second-quarter results, with revenue beating Wall Street expectations while its quarterly loss came in wider than analysts had forecast as the company incurred restructuring charges tied to its shift toward branded GLP-1 weight-loss options. Revenue for the quarter ended June 30 rose 38% year over year to $753.2 million, topping the roughly $699 million analysts had expected. The company reported a loss of $0.37 per share, compared with e", "date_published": "2026-08-11T15:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:32e64489a3d62786fba6caca02d07b57ff35a52a53178385c859292d74424ff6", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-revenue-growth-comes-124948432.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-revenue-growth-comes-124948432.html", "title": "Hims & Hers' Revenue Growth Comes at a Cost", "content_text": "This article first appeared on GuruFocus. Hims & Hers Health, Inc. (NYSE:HIMS) fell 6.11% in premarket after reporting second-quarter revenue of $753.2 million, up 38% year over year and above the $699 million analysts estimate. The company added 452,000 subscribers during the past year, taking its total to 2.89 million, up 19%, while monthly revenue per average subscriber rose 21% to $92. International expansion was a major contributor, with rest-of-world revenue reaching $131.4 million, up more than 17-fold year over year, following the acquisition of Eucalyptus. The headline growth came wit", "date_published": "2026-08-11T12:49:48+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:99c71ad35dfaab6643463965b664764c87288895ec8b78799dc7df60e1f0283b", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-raises-outlook-cash-123343936.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-raises-outlook-cash-123343936.html", "title": "Hims & Hers Raises Outlook as Cash Flow Weakens", "content_text": "This article first appeared on GuruFocus. Hims & Hers Health Inc. (HIMS, Financials) the digital health platform, boosted its full-year revenue outlook after another quarter of robust growth, but investors are also getting a better sense of what that expansion will cost. Warning! GuruFocus has detected 3 Warning Signs with HIMS. Is HIMS fairly valued? Test your thesis with our free DCF calculator. Revenue for the second quarter jumped about 40 percent from a year ago, to well over $753 million, as the firm added more than 300,000 subscribers and pushed its global client base to nearly 3 millio", "date_published": "2026-08-11T12:33:43+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:4ead6733f84ff1d5880ed93148c0b89a4e5eb1471c235279bfa3525b509a2a72", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-earnings-look-121322097.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-earnings-look-121322097.html", "title": "Hims & Hers Health Earnings: What To Look For From HIMS", "content_text": "Hims & Hers Health Earnings: What To Look For From HIMS Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here's what to expect. Hims & Hers Health missed analysts' revenue expectations last quarter, reporting revenues of $608.1 million, up 3.8% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. It added 73,000 customers to reach a total of 2.58 million. Is Hims & Hers Health a buy or sell g", "date_published": "2026-08-11T12:13:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:a42bc91beca458a10671b09b8feaf2cff3b5d7f834935bd62b20bbc5a1440dfa", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-q2-2026-earnings-112311704.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-q2-2026-earnings-112311704.html", "title": "Hims & Hers Q2 2026 earnings: loss despite revenue beat", "content_text": "Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million. The company raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion, up from a prior target of $2.8 billion to $3 billion, the company said. It also updated its adjusted EBITDA guidance to a range of $275 million to $325 million. Analysts had expected full-year revenue of $2.93 billion, according to Benzinga. Quarterly revenue of $753.2 million beat analyst", "date_published": "2026-08-11T11:23:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:f0bd315910f4954329b38ebacb44e6fd753c8869304eeb828c572073b4714952", "url": "https://seekingalpha.com/news/4630448-hims-and-hers-anticipates-880m-900m-q3-revenue-while-raising-2026-outlook-to-3_1b-3_3b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4630448-hims-and-hers-anticipates-880m-900m-q3-revenue-while-raising-2026-outlook-to-3_1b-3_3b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Hims & Hers anticipates $880M-$900M Q3 revenue while raising 2026 outlook to $3.1B-$3.3B", "content_text": "Earnings Call Insights: Hims & Hers Health (HIMS) Q2 2026 MANAGEMENT VIEW * \"In the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people.\" (Co-Founder, Chairman & CEO Andrew Dudum) * \"In June, we became the leading global consumer health platform when we closed our acquisition of Eucalyptus.\" (Co-Founder, Chairman & CEO Andrew Dudum) * \"Only three quarters after launch, testosterone is scaling faster than any other specialty outside of weight loss.\" (Co-Founder, Chairman & CEO Andrew Dudum) * \"We are currently developing a be", "date_published": "2026-08-11T05:49:57+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Deals and strategy", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:394daa156c2c9e9e171d510276a9617dc094710fd352bb43777640103e3cb2b5", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-hims-050129793.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-hims-050129793.html", "title": "Hims & Hers Health Inc (HIMS) (Q2 2026) Earnings Call Highlights: Revenue Surges 40% to ...", "content_text": "This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International Revenue: Increased over 17-fold year-over-year to $131 million. Adjusted EBITDA: $60 million, representing an 8% margin. Gross Margin: 64%, down approximately six points quarter-over-quarter on an adjusted basis. GAAP Net Income: Loss of $86 million, impacted by non-recurring acq", "date_published": "2026-08-11T05:01:29+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:57fc5bb8b8ae76eab37703766e91293fa91b1246597f3eab686cf73b5a35c204", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-hims-215505683.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-hims-215505683.html", "title": "Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates", "content_text": "Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -42.86%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced a loss of $0.18, delivering a surprise of -550%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Hims & Hers Health, which belongs t", "date_published": "2026-08-10T21:55:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:89aa40cb6c3689844c6f009195e41b857678c50296746016c09ab7dea2d75425", "url": "https://finance.yahoo.com/video/hims-hers-lowers-profit-forecast-212732082.html", "external_url": "https://finance.yahoo.com/video/hims-hers-lowers-profit-forecast-212732082.html", "title": "Hims & Hers Lowers Profit Forecast, Shares Drop", "content_text": "Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on \"Bloomberg The Close.\" View Comments", "date_published": "2026-08-10T21:27:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:ed286af6b6de07313445863cfd7aeb8c8cc507d3a2353012df48364b401ee7e8", "url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "external_url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "title": "Hims Stock Falls on Earnings. Why a Guidance Hike Isn\u2019t Enough.", "content_text": "Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading", "date_published": "2026-08-10T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:1eda413c346ff1e466edc561cab8f58ec07bb657f17c6d0e478cb4db45dcee50", "url": "https://finance.yahoo.com/m/a1d3cbfb-8db8-3ad0-a49f-21941c47a99c/hims-topples-as-obesity.html", "external_url": "https://finance.yahoo.com/m/a1d3cbfb-8db8-3ad0-a49f-21941c47a99c/hims-topples-as-obesity.html", "title": "Hims Topples As Obesity Kingpin Hits A Snag On Weighty Second-Quarter Loss", "content_text": "Hims stock fell late Monday after its second-quarter loss came in bigger than expected, upsetting a sales beat. Continue Reading", "date_published": "2026-08-10T20:45:51+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:12a62f3e73ade9f240ba15cad85ae63193082bd7032bf69877af0df7f2f99e2c", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-shares-fall-second-204424717.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-shares-fall-second-204424717.html", "title": "Hims & Hers shares fall after second-quarter wider-than-expected loss", "content_text": "Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%. The company reported a loss of 37 cents per share, compared with analysts' estimate of a loss of 5 cents per share. Revenue rose 38% year over year to $753.2 million, beating the $691.65 million consensus estimate. The company, however, raised its forecast for 2026 and it now expects FY revenue of $3.1 billion to $3.3 billion, and adjusted EBITDA of $275 million to $325 million. It expects third-quarter revenue of $880 million to $900 million and adjusted EBITDA of $7", "date_published": "2026-08-10T20:44:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:5b9a36374ccedaacce4adea50b202b9bdcea1c0f2df2917ba2628217985201e3", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-nyse-hims-201707139.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-nyse-hims-201707139.html", "title": "Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops", "content_text": "Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter's revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its GAAP loss of $0.37 per share was significantly below analysts' consensus estimates. Is now the time to buy Hims & Hers Health? Find out in our full research report. Hims & Hers Health (HIMS) Q2 CY2026 H", "date_published": "2026-08-10T20:17:07+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:b36516cda3daacb737b71aeebf9a309a1f88e174240151591b459b674a714a36", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-reports-200500963.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-inc-reports-200500963.html", "title": "Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results", "content_text": "Revenue of approximately $753 million, up 38% year-over-year in Q2 2026 Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026 Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to a range of $275 million to $325 million SAN FRANCISCO, August 10, 2026--(BUSINESS WIRE)--Hims & Hers Health, Inc. (\"Hims & Hers\" or the \"Company\", NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second quarter ended June 30, 2026. \"Hims & Hers is delivering a world-class healt", "date_published": "2026-08-10T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:1e0481dfb0bc0334e43ac1edaf267965586f82fa7050510adf9c568f7082cadd", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341502/0/en/hims-investigation-alert-kessler-topaz-meltzer-check-llp-encourages-hims-hers-health-inc-nyse-hims-investors-to-contact-the-firm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341502/0/en/hims-investigation-alert-kessler-topaz-meltzer-check-llp-encourages-hims-hers-health-inc-nyse-hims-investors-to-contact-the-firm.html", "title": "HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm", "content_text": "RADNOR, Pa., Aug. 09, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses. HIMS Sued By the Federal Trade Commission On July 29, 2026, the Federal Trade Commission (\u201cFTC\u201d) filed a lawsuit against HIMS accusing the company of sharing customers' medical information with third-party", "date_published": "2026-08-09T21:22:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:b79dfef99e14f83e6e7485a496aba4a45ab4c2e909ab425d2433d0cf424e054a", "url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zoetis-q2-earnings-call-highlights-180354196.html", "title": "Zoetis Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand offset growth in livestock, diagnostics and international markets. Pet-care pressures led to a lowered outlook. Declining veterinary visits, selective pet-owner spending and increased competition hurt companion-animal and dermatology sales; Zoetis now expects full-year organic operational revenue to decline 3%", "date_published": "2026-08-09T18:03:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}, {"id": "source:0e2193d480b51858bae723da5e9be28110a742428671295c878f83f7e95e3e4b", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOV2gzLXdzYXpYNXZLM2RMalFfOEc2cFhKckJLa3dqMmJJUWZabEhSYWxQWUdsZG9lV0xsSEtrYnhnbmFDdGN6cXJ6YVRKWVlVZUdQMlJVUUZUeTExZ3JCNVVFT3JXRDFUV3pHdmFwaE1GQnZPNGJiOXBPdW9kdG9PSG4tbkpiUzNla0FfU2JQSnB3M204U1J4MVVZU1VxQTJ3V0dvYnE0QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOV2gzLXdzYXpYNXZLM2RMalFfOEc2cFhKckJLa3dqMmJJUWZabEhSYWxQWUdsZG9lV0xsSEtrYnhnbmFDdGN6cXJ6YVRKWVlVZUdQMlJVUUZUeTExZ3JCNVVFT3JXRDFUV3pHdmFwaE1GQnZPNGJiOXBPdW9kdG9PSG4tbkpiUzNla0FfU2JQSnB3M204U1J4MVVZU1VxQTJ3V0dvYnE0QQ?oc=5", "title": "Zoetis Cut Its 2026 Guide in Q2 Earnings. The Dermatology Lead Is the Reason.", "content_text": "Zoetis Cut Its 2026 Guide in Q2 Earnings. The Dermatology Lead Is the Reason.", "date_published": "2026-08-08T15:52:43+00:00", "authors": [{"name": "TIKR.com"}], "tags": ["Earnings", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}, {"id": "source:2995c260e586e447e2c908e60a4b36a3e1b2a827b8cf51d25badec61c8c08285", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-hims-responds-081252527.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-hims-responds-081252527.html", "title": "Hims & Hers Health (HIMS) Responds To FTC Lawsuit Over Patient Data Use", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices and use of patient data. The company addressed the FTC action by outlining its position on how it handles telehealth consultations and consumer information, aiming to reassure users and investors. The lawsuit raises questions about regulatory risk for telehealth providers and how patient data is collected, st", "date_published": "2026-08-08T08:12:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:ef222b2a44d8baabba4b61c92f045fc54396216d16f5a35441d46a15e3a728d1", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-hims-launches-221306592.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-health-hims-launches-221306592.html", "title": "Hims & Hers Health (HIMS) Launches AI Weight Loss Care, Is It Still A Bargain?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Hims & Hers Health (HIMS) just introduced an AI powered care experience for Hers weight loss members, including a connected smart scale and app based coaching, giving investors fresh information on its digital health approach. See our latest analysis for Hims & Hers Health. The AI powered weight loss rollout comes at a time when Hims & Hers Health has experienced sharp swings in sentiment, with the share price up 6.51% on the day and 13.76% over seven days, yet down 12.42% ov", "date_published": "2026-08-07T22:13:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:8004fd853e391170d408acdf46099631862c9e44c9ca6bd2e91e516fef1f950f", "url": "https://www.globenewswire.com/news-release/2026/08/07/3341342/0/en/hims-hers-health-investor-alert-bragar-eagel-squire-p-c-is-investigating-hims-hers-health-inc-on-behalf-of-hims-hers-stockholders-and-encourages-investors-to-contact-the-firm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/07/3341342/0/en/hims-hers-health-investor-alert-bragar-eagel-squire-p-c-is-investigating-hims-hers-health-inc-on-behalf-of-hims-hers-stockholders-and-encourages-investors-to-contact-the-firm.html", "title": "HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm", "content_text": "Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Hims & Hers and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. Click here to participate in the action. NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- What\u2019s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm,", "date_published": "2026-08-07T19:07:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:5684c49208054ce7e380dd7f9ed98d644471ca0866537bb5f9ac6270115cadae", "url": "https://finance.yahoo.com/healthcare/articles/weight-loss-momentum-lift-hims-175400519.html", "external_url": "https://finance.yahoo.com/healthcare/articles/weight-loss-momentum-lift-hims-175400519.html", "title": "Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?", "content_text": "Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2026 results on Aug. 10, after the closing bell. In the last reported quarter, the company's loss per share of 18 cents lagged the Zacks Consensus Estimate of earnings per share of 4 cents. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on one occasion and missed thrice, delivering a negative earnings surprise of 84.7%, on average. Let's check out the factors that have shaped HIMS' performance prior to this announcement. Factors to Note Before Hims & Hers Reports Hims & Hers' second-qua", "date_published": "2026-08-07T17:54:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "HIMS & HERS HEALTH INC", "sentiment_url": "https://sharemaestro.com/sentiment/47f5b4c1-5a86-4e9b-9cbf-56c7e154cc1c/"}]}}, {"id": "source:636c255d33391d4a2eab259f8f5d9b439e03897eb52e0992a9857e6afa2d29bb", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNTU5MSm1Qa1JFa1VEcWhEMXNlVHpWNVNaYnJmVFlTOVNOYUNKVjF3Wl9Xa21iaGNpWVZnaGpfQzMwVXA5bk9wNGhSdklodWRILXFlRkVzSWNKb2pudlBUZUNXallURWFRNm5YaFpDMEJFWjh0YmhGdl9OcmlpSWFiVUFtWWZrbVRVd25pbmtIaXhnaDFUdjd1aU52YjliR2ZkSGwwOVY4NWFRbDNZSkJsTHdpelE2ekZEVDl0SnVpRDJPOHRRT3FCVXB4NXQ2VkMyVUZpQ2owWkRXZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNTU5MSm1Qa1JFa1VEcWhEMXNlVHpWNVNaYnJmVFlTOVNOYUNKVjF3Wl9Xa21iaGNpWVZnaGpfQzMwVXA5bk9wNGhSdklodWRILXFlRkVzSWNKb2pudlBUZUNXallURWFRNm5YaFpDMEJFWjh0YmhGdl9OcmlpSWFiVUFtWWZrbVRVd25pbmtIaXhnaDFUdjd1aU52YjliR2ZkSGwwOVY4NWFRbDNZSkJsTHdpelE2ekZEVDl0SnVpRDJPOHRRT3FCVXB4NXQ2VkMyVUZpQ2owWkRXZw?oc=5", "title": "Informe de resultados: Zoetis presenta resultados mixtos en el segundo trimestre de 2026", "content_text": "Informe de resultados: Zoetis presenta resultados mixtos en el segundo trimestre de 2026", "date_published": "2026-08-06T14:50:00+00:00", "authors": [{"name": "Investing.com Espa\u00f1a"}], "tags": ["Market update", "ZTS"], "_sharemaestro": {"country": "Mexico", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZTS", "name": "Zoetis Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d99acf02-a6bb-4ac1-96cc-9b1cace7f412/"}]}}]}